[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]

Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies. Primary antifungal prophylaxis (PAP) is effective for decreasing incidence of IFD, and the patients will be more tolerable to chemotherapy with less cost and better prognosis. Antifungal drugs as fluconazole, itraconazole, posaconazole, caspofungin and micafungin are all recommended for PAP by many consensus and guidelines. The PAP will be more scientific, appropriate and effective with the development of studies about predicting risk-stratification for IFD, new drugs, pharmacokinetics and integrated prophylaxis. This review summarizes the progress of PAP in hematological malignancy patients in recent years.